aiolosbio.comHealthcare / BioTech & PharmaFounded: 2023Funding to Date: $247.55MM
Aiolos Bio is revolutionizing treatments for respiratory diseases and immune conditions, aiming to deliver innovative therapies to patients and caregivers. With a seasoned team boasting over 30 FDA approvals, Aiolos Bio is developing effective treatments for asthma, rheumatoid arthritis, and IPF. The company focuses on a groundbreaking anti-TSLP asset, which is expected to enhance efficacy with less frequent dosing than current treatments. Aiolos Bio's mission is to reduce treatment burden and improve patient care through more efficacious therapies.
View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies.
Become part of the Secondary Marketplace, catering to both individual and institutional investors.